Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.

You may also be interested in...

Paying For Placebo Is ‘Biggest Change’ In Medicare CED Policy, Official Says

The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo in clinical trials required under a ‘coverage with evidence development’ determination as a major improvement in its recent guidance for CED.

Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors

Agency decides against requiring coverage with evidence development for off-label uses.

Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS

Policy had been used to limit expenditures for prostate cancer drugs and inhaled drugs for pulmonary disease.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts